Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination
| Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination |
| Autore | Alix-Panabieres Catherine |
| Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (366 p.) |
| Soggetto non controllato |
FOLFIRINOX
immunofluorescence imaging AR-V7 circulating tumour cells chemoradioresistance CTC-based treatment decisions rVAR2 immunophenotyping immune system CellSearch® flow cytometry clinical trials circulating tumor DNA synaptophysin stem cells colorectal cancer melanoma CTC biology platelets AR CTC capture technology castration resistant prostate cancer (CRPC) PD-L1 expression rovalpituzumab tesirine HMB-45 thymidylate synthase ctDNA tumor cell dissemination solid cancers metastasis locally advanced rectal cancer miRNA epithelial-to-mesenchymal transition (EMT) NSCLC tumor biomarkers tumor stem cells circulating tumor cells major histocompatibility complex class I (MHCI) bone marrow heterogeneity cerebrospinal liquid biopsy fish glioma in vivo flow cytometry colorectal surgery CellSearch single-cell analysis disseminated tumor cells EasyCount slides microsatellite instability circulating plasma cells circulating leukemia cells ARV7 SLUG androgen receptor metastatic colorectal cancer leukocyte-derived extracellular vesicles prostate cancer (PCa) neutrophils liquid biopsy enzalutamide CD133 enrichment and detection technologies biomarkers immune checkpoint inhibitors biomarker RAD23B microbiome integrin B1 ACCEPT emboli small-cell lung carcinoma EPISPOT microfluidics early breast cancer circulating tumor cells (CTC) tumor-initiating cells (TICs) immunomodulation xenograft models CTC-derived xenografts malaria circulating tumor cells (CTCs) clinical utility exosomes liquid surgery ctRNA CTCs epithelial-mesenchymal transition targeted therapy hematological cells gene expression analysis hepatocellular carcinoma (HCC) breast cancer EpCAM enrichment prostate cancer CTC abiraterone fibronectin CTC-derived ex vivo models CTMat chromogranin A CTM exosome |
| ISBN | 3-03928-699-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Circulating Tumor Cells |
| Record Nr. | UNINA-9910404091403321 |
Alix-Panabieres Catherine
|
||
| MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Targeting STAT3 and STAT5 in Cancer
| Targeting STAT3 and STAT5 in Cancer |
| Autore | Moriggl Richard |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (578 p.) |
| Soggetto topico |
Research & information: general
Biology, life sciences |
| Soggetto non controllato |
multiple myeloma
STAT3 S3I-1757 nanoparticle CD38 siRNA/RNAi polyethylenimine PEI lipopolyplex siRNA delivery glioma glioblastoma STAT5 AKT ERK1/2 prolactin androgens prostate cancer knockout escape mechanisms stem/progenitor cells cell hierarchy cancer CD4+ T cells CD8+ T cells myeloid cells immune check point hepatitis C virus (HCV) cirrhosis hepatocellular carcinoma (HCC) endoplasmic reticulum (ER) stress oxidative stress (OS) unfolded protein response (UPR) microRNA-122 (miR-122) nuclear factor erythroid 2-related factor 2 (NRF2) signal transducer and activator of transcription 3 (STAT3) hepatocyte nuclear factor 4 alpha (HNF4A) solid cancers cell cycle apoptosis inflammation mitochondria stemness tumor suppression melanoma autoimmune disease immunotherapy tumor-immune cell interactions breast cancer PD-L1 M2 macrophages NK cells STAT3 inhibitor XIII hedging transaction costs dynamic programming risk management post-decision state variable cancer progression cancer-stem cell cytokine therapy resistance metastasis immunosuppression tumor microenvironment proliferation tyrosine kinase 2 JAK family of protein tyrosine kinases signal transducer and activator of transcription cytokine receptor signaling gain-of-function mutation tumorigenesis ADAM17 interleukin-6 trans-signaling epidermal growth factor receptor (EGF-R) shedding metalloprotease tumor necrosis factor alpha (TNFα) inflammation associated cancer colon cancer lung cancer SH2 domain mutations autosomal-dominant hyper IgE syndrome inflammatory hepatocellular adenomas T-cell large granular lymphocytic leukemia T-cell prolymphocytic leukemia growth hormone insensitivity syndrome nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling targeting tumor-associated macrophages adoptive T cell therapy immune suppression STAT transcription factors JAK STAT T-PLL T-cell leukemia meta-analysis STAT5B signaling small-molecule inhibitors cancer models companion animals comparative oncology pharmacological inhibitor STAT5 signaling chemotherapy resistance myeloid leukemia heat shock proteins chaperones stabilization targeted therapy ovarian cancer hematopoietic cancers therapeutic targeting pharmacological inhibitors mTOR Bone Marrow Failure Syndromes lymphocytes lymphoma T-cells RHOA NGS MPN JAK2 V617F neoplastic stem cells |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557623503321 |
|
Moriggl Richard
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||